Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;26(1):2545057.
doi: 10.1080/15384047.2025.2545057. Epub 2025 Aug 8.

Unraveling the dual role of METTL3-mediated m6A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications

Hua Chun  1 , Kangzhuo Baima  1
Affiliations
Review

Unraveling the dual role of METTL3-mediated m6A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications

Hua Chun et al. Cancer Biol Ther. 2025 Dec.

Abstract

Bladder cancer (BC) remains challenging due to its recurrence and metastasis, with METTL3-mediated m6 A RNA modification emerging as a key oncogenic driver. This review synthesizes METTL3's roles in BC progression, including tumor initiation, metastasis, stemness, and therapy resistance. We detail its regulation of critical pathways (e.g. HIF1A/IGF2BP3/BIRC5, AFF4/NF-κB/c-MYC) and dual functions in RNA stability and epigenetic crosstalk with DNA methylation. METTL3 promotes chemoresistance (e.g. circ0008399/WTAP/TNFAIP3) and immune evasion (PD-L1 stabilization), while its overexpression correlates with poor prognosis and cisplatin resistance. By integrating METTL3's interactions with m6 A readers (YTHDF1/2, IGF2BP3) and erasers (ALKBH5), we propose targeting METTL3 as a strategy to enhance chemotherapy and immunotherapy efficacy. This work underscores METTL3's potential as a diagnostic biomarker and therapeutic target, advancing precision oncology in BC.

Keywords: Bladder cancer; METTL3; RNA m6A modification; chemoresistance; epitranscriptomics; immune evasion; therapeutic targeting.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
METTL3-centric network driving BC pathogenesis.
See this image and copyright information in PMC

References

    1. Laversanne M, Nagy P, Kenessey I, Znaor A.. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237. doi: 10.1007/s00345-024-04949-8. - DOI - PMC - PubMed
    1. Su X, Tao Y, Chen F, Han X, Xue L. Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021. Sci Rep. 2025;15(1):7655. doi: 10.1038/s41598-025-92033-5. - DOI - PMC - PubMed
    1. Grobet-Jeandin E, Lenfant L, Mir C, Giannarini G, Alcaraz A, Albersen M, Breda A, Briganti A, Rouprêt M, Seisen T. A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Eur Urology Oncol. 2023;6(3):251–13. doi: 10.1016/j.euo.2023.02.008. - DOI - PubMed
    1. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m6 a RNA methylation. Nat Rev Genet. 2014;15(5):293–306. doi: 10.1038/nrg3724. - DOI - PubMed
    1. Zhang H, Shi X, Huang T, Zhao X, Chen W, Gu N, Zhang R. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–6264. doi: 10.1093/nar/gkaa347. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources